B. Riley Wealth Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$770K Buy
4,886
+44
+0.9% +$6.6K 0.04% 364
2026
Q1
$728K Sell
4,842
-1,944
-29% -$298K 0.05% 354
2025
Q4
$936K Sell
6,786
-1,186
-15% -$155K 0.04% 359
2025
Q3
$1.02M Sell
7,972
-1,248
-14% -$152K 0.05% 335
2025
Q2
$1.12M Buy
+9,220
New +$1.04M 0.05% 332
2024
Q4
$1.92M Sell
19,769
-2,783
-12% -$297K 0.06% 288
2024
Q3
$2.59M Sell
22,552
-2,447
-10% -$278K 0.07% 269
2024
Q2
$2.66M Sell
24,999
-2,075
-8% -$208K 0.07% 275
2024
Q1
$2.76M Buy
27,074
+295
+1% +$30.2K 0.07% 263
2023
Q4
$2.7M Sell
26,779
-295
-1% -$28.5K 0.07% 275
2023
Q3
$2.76M Sell
27,074
-950
-3% -$96.4K 0.07% 263
2023
Q2
$2.83M Buy
28,024
+1,833
+7% +$183K 0.06% 285
2023
Q1
$2.41M Sell
26,191
-387
-1% -$33.8K 0.06% 301
2022
Q4
$2.41M Sell
26,578
-1,171
-4% -$98.6K 0.07% 296
2022
Q3
$2.11M Buy
27,749
+5,834
+27% +$484K 0.06% 299
2022
Q2
$1.85M Buy
21,915
+749
+4% +$65.7K 0.08% 263
2022
Q1
$1.86M Buy
21,166
+717
+4% +$62.1K 0.06% 315
2021
Q4
$1.79M Sell
20,449
-2,306
-10% -$191K 0.05% 382
2021
Q3
$1.87M Sell
22,755
-94
-0.4% -$8.46K 0.06% 358
2021
Q2
$2.08M Buy
22,849
+262
+1% +$23.3K 0.07% 324
2021
Q1
$1.94M Buy
22,587
+15,124
+203% +$1.36M 0.07% 312
2020
Q4
$707K Sell
7,463
-1,401
-16% -$122K 0.04% 433
2020
Q3
$772K Buy
8,864
+2,463
+38% +$213K 0.04% 386
2020
Q2
$560K Buy
6,401
+382
+6% +$33K 0.04% 418
2020
Q1
$497K Buy
6,019
+1,418
+31% +$127K 0.04% 385
2019
Q4
$436K Buy
4,601
+420
+10% +$37.7K 0.04% 480
2019
Q3
$364K Sell
4,181
-920
-18% -$82.6K 0.04% 521
2019
Q2
$467K Sell
5,101
-588
-10% -$49.8K 0.05% 402
2019
Q1
$491K Buy
5,689
+423
+8% +$34K 0.06% 352
2018
Q4
$406K Buy
5,266
+715
+16% +$55.7K 0.06% 358
2018
Q3
$352K Buy
4,551
+1,042
+30% +$77K 0.04% 445
2018
Q2
$238K Buy
3,509
+205
+6% +$14.1K 0.03% 554
2018
Q1
$241K Buy
3,304
+474
+17% +$36.1K 0.03% 523
2017
Q4
$215K Buy
+2,830
New +$214K 0.03% 557
2017
Q3
Sell
-3,410
Closed -$256K 577
2017
Q2
$256K Buy
+3,410
New +$242K 0.05% 410
2016
Q4
Sell
-3,263
Closed -$233K 605
2016
Q3
$233K Buy
3,263
+107
+3% +$7.8K 0.05% 493
2016
Q2
$235K Sell
3,156
-3,157
-50% -$218K 0.05% 486
2016
Q1
$410K Sell
6,313
-711
-10% -$48.4K 0.09% 262
2015
Q4
$544K Sell
7,024
-1,008
-13% -$80.1K 0.11% 226
2015
Q3
$664K Buy
8,032
+320
+4% +$28.5K 0.16% 175
2015
Q2
$682K Buy
7,712
+1,246
+19% +$114K 0.17% 168
2015
Q1
$571K Sell
6,466
-2,762
-30% -$245K 0.14% 191
2014
Q4
$5.97K Buy
+9,228
New +$765K 0.13% 197
2014
Q3
Sell
-9,947
Closed -$807K 1466
2014
Q2
$807K Buy
9,947
+7,873
+380% +$619K 0.19% 115
2014
Q1
$158K Buy
+2,074
New +$151K 0.05% 464

Other funds holding NVS

B. Riley Wealth Advisors's NVS Position: Q2 2026 in Review

B. Riley Wealth Advisors increased its Novartis (NVS) stake by 0.91% in Q2 2026, buying an estimated $6.6K and bringing the position to 4,886 shares worth $770K. The position accounts for 0.04% of the portfolio, ranked #364.

B. Riley Wealth Advisors first reported a position in NVS in Q1 2014 and has held it in 45 quarters since. The position peaked at $2.83M in Q2 2023. 437 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • B. Riley Wealth Advisors held 4,886 shares of Novartis worth $770K as of Q2 2026.
  • B. Riley Wealth Advisors bought 44 Novartis shares in Q2 2026, an estimated $6.6K.
  • Novartis made up 0.04% of B. Riley Wealth Advisors's portfolio in Q2 2026, its #364 holding.
  • B. Riley Wealth Advisors first reported a position in Novartis in Q1 2014 and has held it in 45 quarters since.
  • B. Riley Wealth Advisors's Novartis position peaked at $2.83M in Q2 2023.
  • 437 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.